Affiliation:
1. Ryzhikh National Medical Research Center of Coloproctology
2. Ryzhikh National Medical Research Center of Coloproctology;
Russian Medical Academy of Continuous Professional Education
Abstract
AIM: to study the effect of total neoadjuvant therapy with consolidation chemotherapy for rectal cancer.MATERIALS AND METHODS: the meta-analysis performed in accordance with PRISMA practices and guidelines.RESULTS: short-course radiotherapy with consolidation chemotherapy compared to chemoradiotherapy (CRT) improves the rate of complete pathological responses (OR = 1.88; CI 1.47–2.42; p < 0.00001); does not affect the rate of local relapses (OR = 0.95; CI 0.72–1.24; p = 0.69), three-year disease-free survival (OR = 1.19; CI 0.99–1.44; p = 0.06) and overall survival (OR = 1.09; CI 0.88–1.35; p = 0.45). TNT increases the incidence of grade ≥ 3 toxicity (OR = 1.87; CI 1.10–3.18; p = 0.02), and does not affect treatment compliance (OR = 0.57; CI 0.17–1.95; p = 0.37).CONCLUSION: the use of TNT can improve the oncological results of treatment of patients with rectal cancer by increasing the frequency of complete pathological responses.
Publisher
Russian Association of Coloproctology
Reference22 articles.
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Rectal Cancer Version 4.2023 — July 25, 2023.
2. Goffredo P, Quezada-Diaz FF, Garcia-Aguilar J, et al. Non-Operative Management of Patients with Rectal Cancer: Lessons Learnt from the OPRA Trial. Cancers (Basel). 2022 Jun 30;14(13):3204. doi: 10.3390/cancers14133204 PMID: 35804975; PMCID: PMC9264788.
3. Fokas E, Allgäuer M, Polat B, et al. German Rectal Cancer Study Group. Randomized Phase II Trial of Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer: CAO/ARO/AIO-12. J Clin Oncol. 2019 Dec 1;37(34):3212–3222. doi: 10.1200/JCO.19.00308 Epub 2019 May 31. PMID: 31150315.
4. Moher D. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med. 2009 Jul;6(7):e1000097.
5. Bahadoer RR, Dijkstra EA, van Etten B, et al. RAPIDO collaborative investigators. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy in locally advanced rectal cancer (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021 Jan;22(1):29–42. doi: 10.1016/S1470-2045(20)30555-6 Epub 2020 Dec 7. Erratum in: Lancet Oncol. 2021 Feb;22(2):e42. PMID: 33301740.